NCT06104566Phase 3Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

Study sponsor: Ascentage Pharma Group Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-12-31Estimated
Enrollment · participants400Estimated
Source updated2026-06-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: 20 Oct 2025. After: 31 Dec 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview